低疾病活动度、缓解和完全缓解对系统性红斑狼疮患者减停糖皮质激素和免疫抑制剂后复发的影响:一项多国队列研究
这项多国队列研究纳入3002例稳定期系统性红斑狼疮(SLE)患者,比较减药与维持治疗后的复发风险。减药与更高的复发风险相关(OR 1.24,95%CI 1.10-1.39;p=0.0005)。在完全缓解期启动减药,其1年内复发风险和至首次复发时间均优于低疾病活动度(LLDAS)或缓解期启动减药。
要点
- 稳定期SLE患者减停糖皮质激素或免疫抑制剂与更高的复发风险相关(OR 1.24,95%CI 1.10-1.39;p=0.0005)。
- 在LLDAS期启动减药的1年内复发风险高于完全缓解期(OR 1.37,95%CI 1.03-1.81;p=0.029)。
- 减药前维持LLDAS、缓解或完全缓解至少6个月与更低的复发风险和更长的至复发时间相关。
核心结论
- 稳定期SLE患者减停糖皮质激素或免疫抑制剂与复发增加相关。
- 作者认为减药应仔细权衡风险与获益,最好在完全(临床和血清学)缓解且稳定病情维持至少6个月后进行。
研究设计与样本
- 多国队列研究,在13个亚太国家的25个中心开展,纳入18岁及以上、接受常规临床诊疗、有两次及以上访视且至少一次访视达到稳定疾病的成人SLE患者。
- 2013年5月1日至2020年12月31日共招募4106例患者,其中3002例(73.1%)纳入分析;2769例(92.2%)为女性,233例(7.8%)为男性;2993例有族裔数据的患者中2636例(88.1%)为亚洲人;中位年龄39.5岁(IQR 29.0-50.0)。
- 稳定疾病分为互斥的三类:LLDAS(SLEDAI-2K评分≤4、PGA≤1且泼尼松龙≤7.5 mg/天)、DORIS缓解(临床SLEDAI-2K评分0、PGA<0.5且泼尼松龙≤5 mg/天)或治疗中完全缓解(SLEDAI-2K评分0、PGA<0.5且泼尼松龙≤5 mg/天)。
- 减药定义为糖皮质激素或免疫抑制剂(吗替麦考酚酯、钙调神经磷酸酶抑制剂、硫唑嘌呤、来氟米特或甲氨蝶呤)任何剂量的降低;采用多变量广义估计方程比较减药后下次访视时的复发(SELENA-SLEDAI复发指数),并用广义估计方程和Cox比例风险模型比较在LLDAS、缓解和完全缓解期启动的减药尝试。
主要发现
- LLDAS、缓解或完全缓解患者共14808次访视,排除缺失数据后13140次(88.7%)进入最终多变量模型。
- 维持原治疗的9863次访视中,1121次(11.4%)在下次访视时复发,其中221次(19.7%)为严重复发;减药的3277次访视中,557次(17.0%)在下次访视时复发,其中120次(21.5%)为严重复发。
- 与维持原治疗相比,减药与更高的复发风险相关(OR 1.24,95%CI 1.10-1.39;p=0.0005)。
- 2095次连续减药尝试中,860次(41.1%)在LLDAS期启动,596次(28.4%)在缓解期启动,639次(30.5%)在完全缓解期启动;与完全缓解期启动相比,LLDAS期启动(OR 1.37,95%CI 1.03-1.81;p=0.029)或缓解期启动(OR 1.45,95%CI 1.08-1.94;p=0.013)的1年内复发风险更高。
- 与完全缓解期启动减药相比,LLDAS期启动(HR 1.24,95%CI 1.04-1.48;p=0.016)或缓解期启动(HR 1.30,95%CI 1.08-1.56;p=0.0054)的至首次复发时间显著更短。
关键数值与推荐
- LLDAS定义:SLEDAI-2K评分≤4、PGA≤1且泼尼松龙≤7.5 mg/天。
- DORIS缓解定义:临床SLEDAI-2K评分0、PGA<0.5且泼尼松龙≤5 mg/天。
- 治疗中完全缓解定义:SLEDAI-2K评分0、PGA<0.5且泼尼松龙≤5 mg/天。
- 减药定义为糖皮质激素或免疫抑制剂(吗替麦考酚酯、钙调神经磷酸酶抑制剂、硫唑嘌呤、来氟米特或甲氨蝶呤)任何剂量的降低。
- 复发采用SELENA-SLEDAI复发指数评估。
临床怎么用
- 作者认为,稳定期SLE患者减停糖皮质激素或免疫抑制剂应仔细权衡风险与获益。
- 作者认为,减药最好在完全(临床和血清学)缓解且稳定病情维持至少6个月后进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targets of treatment for systemic lupus erythematosus (SLE) include the Lupus Low Disease Activity State (LLDAS), remission, and complete remission. Whether treatment can be tapered after attaining these targets and whether tapering is safer in patients in complete remission compared with LLDAS are unknown. We aimed to assess the odds of disease flares after treatment tapering in stable disease, versus continuing the same therapy. We also aimed to examine whether tapering in complete remission resulted in fewer flares or longer time to flare compared with tapering in LLDAS or remission. METHODS: This multinational cohort study was conducted at 25 sites across 13 Asia-Pacific countries. We included adult patients aged 18 years or older with stable SLE who were receiving routine clinical care, had two or more visits and had attained stable disease at one or more visits. We categorised stable disease into: LLDAS (Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K] score ≤4, Physician Global Assessment [PGA] ≤1, and prednisolone ≤7·5 mg/day); Definitions of Remission in SLE (DORIS) remission (clinical SLEDAI-2K score 0, PGA <0·5, and prednisolone ≤5 mg/day); or complete remission on therapy (SLEDAI-2K score 0, PGA <0·5, and prednisolone ≤5 mg/day). Stable disease categories were mutually exclusive. Tapering was defined as any decrease in dose of corticosteroids or immunosuppressive therapy (mycophenolate mofetil, calcineurin inhibitors, azathioprine, leflunomide, or methotrexate). Using multivariable generalised estimating equations, we compared flares (SELENA-SLEDAI Flare Index) at the subsequent visit after drug tapering. We used generalised estimating equations and Cox proportional hazard models to compare tapering attempts that had begun in LLDAS, remission, and complete remission. FINDINGS: Between May 1, 2013, and Dec 31, 2020, 4106 patients were recruited to the cohort, 3002 (73·1%) of whom were included in our analysis. 2769 (92·2%) participants were female, 233 (7·8%) were male, and 2636 (88·1%) of 2993 with ethnicity data available were Asian. The median age was 39·5 years (IQR 29·0-50·0). There were 14 808 patient visits for patients in LLDAS, or remission or complete remission, of which 13 140 (88·7%) entered the final multivariable model after excluding missing data. Among the 9863 visits at which patients continued the same therapy, 1121 (11·4%) flared at the next visit, of which 221 (19·7%) were severe flares. Of the 3277 visits at which a patient received a tapering of therapy, 557 (17·0%) flared at the next visit, of which 120 (21·5%) were severe flares. Tapering was associated with higher odds of flare compared with continuing the same therapy (odds ratio [OR] 1·24 [95% CI 1·10-1·39]; p=0·0005). Of 2095 continuous tapering attempts, 860 (41·1%) were initiated in LLDAS, 596 (28·4%) in remission, and 639 (30·5%) in complete remission. Tapering initiated in LLDAS (OR 1·37 [95% CI 1·03-1·81]; p=0·029) or remission (1·45 [1·08-1·94]; p=0·013) had higher odds of flare in 1 year compared with complete remission. Tapering in LLDAS (hazard ratio 1·24 [95% CI 1·04-1·48]; p=0·016) or remission (1·30 [1·08-1·56]; p=0·0054) had a significantly shorter time to first flare than tapering initiated in complete remission. Attaining sustained LLDAS, remission, or complete remission for at least 6 months just before the time of taper was associated with lower odds of flare at next visit, flares in 1 year, and longer time to flare. INTERPRETATION: Tapering of corticosteroids or immunosuppressive therapy in patients with stable SLE was associated with excess flares. Our findings suggest that drug tapering should be carefully considered, weighing the risks and benefits, and is best exercised in complete (clinical and serological) remission and after maintaining stable disease for at least 6 months. FUNDING: AstraZeneca, BMS, Eli Lily, Janssen, Merck Serono, GSK, and UCB.
引用
- Cho J, Shen L, Huq M, et al. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study. Lancet Rheumatol. 2023. PMID: 38251484. doi:10.1016/S2665-9913(23)00209-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。